Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIG-Immune1
- Development stage
- Discontinued
- Lead developer
- Lmito Therapeutics
- Modality
- Small Molecules
01
Overview
AIG-Immune1 is a small molecule drug that was initially developed by Lmito Therapeutics and Aigen Sciences. It has been investigated for the treatment of immune system diseases, with autoimmune diseases listed as an inactive indication. The drug reached the discovery phase in development but has since been discontinued. Specific details regarding its mechanism of action, molecular target, or chemical structure have not been disclosed in public sources as of June 2025[4].
Beyond the preview
Go deeper on AIG-Immune1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIG-Immune1.